The Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has awarded an Indefinite Delivery Contract (IDC) valued at up to $75 million to Acumen LLC, doing business as Medric, to support the Biologics Effectiveness and Safety (BEST) Initiative #3: Data Sources for Surveillance of Biologics (BEST 3). The contract will provide CBER with access to large-scale, longitudinal healthcare data covering tens of millions of patients, including both administrative claims data and electronic health record data. Medric, as the prime contractor, will be the primary source of this data and will also provide access to full medical charts for patient data review and adjudication in the context of biologic product surveillance activities. This multiple-award IDC has a 5-year ordering period and is not set aside for any specific business size or type. The contract aims to obtain new data sources to support CBER's efforts to monitor the safety and effectiveness of biologics products approved for use in the United States.
Medric holds several other major IDV contracts with the FDA, Centers for Medicare and Medicaid Services, Centers for Disease Control and Prevention, and other HHS agencies, leveraging its expertise in data analytics, research, and technical assistance to support public health surveillance, quality improvement, and value-based payment initiatives across federal healthcare programs.
Generated 9/28/24, 9:03 AM